Stock Events

Stock Events

Taysha Gene Therapies 

$5.57
77
-$0.07-1.24% Thursday 20:00
+$0.08+1.44%Thursday 23:56After hours

Statistics

Day High
5.57
Day Low
5.56
52W High
7.3
52W Low
2.71
Volume
88,617
Avg. Volume
-
Mkt Cap
1.81B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.13
-0.11
-0.09
-0.07
Expected EPS
-0.127617
Actual EPS
N/A

Financials

-1,115.27%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
9.77MRevenue
-109MNet Income

Analyst Ratings

12.71Average Price Target
The highest estimate is 17.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
86%
Hold
14%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TSHA. It's not an investment recommendation.
Microsoft
19
MSFT
Amazon
17
AMZN
NVIDIA
16
NVDA
AMD
14
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, similar to Taysha's focus on gene therapies for CNS disorders.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics is involved in the development of genetically targeted therapies for rare disorders, aligning with Taysha's mission.
Solid Biosciences
SLDB
Mkt Cap1.05B
Solid Biosciences is developing therapies for Duchenne muscular dystrophy, including gene therapies, which puts them in competition with Taysha.
Voyager Therapeutics
VYGR
Mkt Cap218.13M
Voyager Therapeutics specializes in the development of gene therapies for neurodegenerative diseases, directly competing with Taysha's CNS focus.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO, with its focus on AAV gene therapies for a variety of diseases, competes in the same space as Taysha, particularly in CNS disorders.

About

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Show more...
CEO
Sean Nolan
Employees
99
Country
United States
ISIN
US8776191061

Listings

XNAS
US
TSHA
BOATS
BOATS
TSHA.BOATS

0 Comments

Share your thoughts

FAQ

What is Taysha Gene Therapies stock price today?▼
The current price of TSHA is $5.57 USD — it has decreased by -1.24% in the past 24 hours. Watch Taysha Gene Therapies stock price performance more closely on the chart.
What is Taysha Gene Therapies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Taysha Gene Therapies stocks are traded under the ticker TSHA.
Is Taysha Gene Therapies stock price growing?▼
TSHA stock has fallen by -3.47% compared to the previous week, the month change is a -10.16% fall, over the last year Taysha Gene Therapies has showed a +70.86% increase.
What is Taysha Gene Therapies market cap?▼
Today Taysha Gene Therapies has the market capitalization of 1.81B
When is the next Taysha Gene Therapies earnings date?▼
Taysha Gene Therapies is going to release the next earnings report on November 10, 2026.
What were Taysha Gene Therapies earnings last quarter?▼
TSHA earnings for the last quarter are -0.13 USD per share, whereas the estimation was -0.11 USD resulting in a -14.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Taysha Gene Therapies revenue for the last year?▼
Taysha Gene Therapies revenue for the last year amounts to 9.77M USD.
What is Taysha Gene Therapies net income for the last year?▼
TSHA net income for the last year is -109M USD.
How many employees does Taysha Gene Therapies have?▼
As of September 04, 2026, the company has 99 employees.
In which sector is Taysha Gene Therapies located?▼
Taysha Gene Therapies operates in the Health & Wellness sector.
When did Taysha Gene Therapies complete a stock split?▼
Taysha Gene Therapies has not had any recent stock splits.
Where is Taysha Gene Therapies headquartered?▼
Taysha Gene Therapies is headquartered in DALLAS, United States.